To explore the pathogenic link between meta-inflammation and hidradenitis suppurativa (HS), highlighting its significance and discussing therapeutic targets arising from this interplay.
Key Findings:
HS is characterized by chronic inflammation and is associated with systemic conditions like metabolic syndrome.
Meta-inflammation plays a crucial role in the pathogenesis of HS, linking obesity and insulin resistance to disease severity.
The interplay between skin disease and metabolic dysfunction creates a cycle of inflammation and tissue damage, impacting patient quality of life.
Interpretation:
Understanding the relationship between meta-inflammation and HS can inform multidisciplinary treatment approaches.
Limitations:
There is a significant diagnostic delay in HS, impacting timely intervention and treatment outcomes.
Lack of consensus on HS phenotypes and classification hampers clinical assessment.
Conclusion:
The review emphasizes the need for a holistic management strategy that addresses both cutaneous inflammation and metabolic alterations in HS, highlighting the importance of a multidisciplinary approach.
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production
